The <info type="SequenceVariant">fibrinogen gamma 10034C>T</info> polymorphism is not associated with <info type="DiseaseOrPhenotypicFeature">Peripheral Arterial Disease</info>.

Conversion of <info type="GeneOrGeneProduct">fibrinogen</info> to <info type="GeneOrGeneProduct">fibrin</info> plays an essential role in <info type="DiseaseOrPhenotypicFeature">hemostasis</info> and results in stabilization of the <info type="GeneOrGeneProduct">fibrin</info> clot. <info type="GeneOrGeneProduct">Fibrinogen</info> consists of three pairs of non-identical polypeptide chains, encoded by different genes (<info type="GeneOrGeneProduct">fibrinogen alpha [FGA]</info>, <info type="GeneOrGeneProduct">fibrinogen beta [FGB]</info> and <info type="GeneOrGeneProduct">fibrinogen gamma [FGG]</info>). A functional single nucleotide polymorphism (SNP) in the 3' untranslated region of the <info type="GeneOrGeneProduct">FGG</info> gene (<info type="SequenceVariant">FGG 10034C>T</info>, <info type="SequenceVariant">rs2066865</info>) has been associated with <info type="DiseaseOrPhenotypicFeature">deep venous thrombosis</info> and <info type="DiseaseOrPhenotypicFeature">myocardial infarction</info>. Aim of the present study was to analyze the role of this polymorphism in <info type="DiseaseOrPhenotypicFeature">peripheral arterial disease</info> (<info type="DiseaseOrPhenotypicFeature">PAD</info>). The study was designed as case-control study including <info type="CellLine">891 patients</info> with documented <info type="DiseaseOrPhenotypicFeature">PAD</info> and <info type="CellLine">777 control subjects</info>. <info type="GeneOrGeneProduct">FGG</info> genotypes were determined by exonuclease (<info type="GeneOrGeneProduct">TaqMan</info>) assays. <info type="GeneOrGeneProduct">FGG</info> genotype frequencies were not significantly different between <info type="DiseaseOrPhenotypicFeature">PAD</info> patients (CC: 57.3%, CT: 36.7%, TT: 5.8%) and <info type="CellLine">control subjects</info> (CC: 60.9%, CT: 33.5%, TT 5.6%; p=0.35). In a multivariate logistic regression analysis including <info type="GeneOrGeneProduct">age</info>, <info type="GeneOrGeneProduct">sex</info>, <info type="GeneOrGeneProduct">smoking</info>, <info type="GeneOrGeneProduct">diabetes</info>, <info type="GeneOrGeneProduct">arterial hypertension</info> and <info type="GeneOrGeneProduct">hypercholesterolemia</info>, the <info type="SequenceVariant">FGG 10034 T</info> variant was not significantly associated with the presence of <info type="DiseaseOrPhenotypicFeature">PAD</info> (Odds ratio 1.07, 95% confidence interval 0.84 - 1.37; p = 0.60). The <info type="SequenceVariant">FGG 10034C>T</info> polymorphism was furthermore not associated with <info type="GeneOrGeneProduct">age</info> at onset of <info type="DiseaseOrPhenotypicFeature">PAD</info>. We conclude that the thrombophilic <info type="GeneOrGeneProduct">FGG 10034 T</info> gene variant does not contribute to the genetic susceptibility to <info type="DiseaseOrPhenotypicFeature">PAD</info>.